Article content continued

Lobbyists are required to disclose communications with government officials by the 15th of the month following the interaction. On Oct. 12, officials from Apotex lobbied Doug Clark, executive director of the Patented Medicine Prices Review Board. That communication should have been filed by Nov. 15, when Conservative MPs were grilling the Liberals on the fundraisers in the House of Commons.

“Any monthly communication report filed after the 15th of the month following the communication is late,” said a spokesperson for the Office of the Commissioner of Lobbying, adding: “In cases of late filing, the Office contacts the registrant and ensures that they understand the requirement in the Lobbying Act to file communication reports on time.” Apotex did not immediately respond to a request for comment.

In September 2014, the Federal government banned Apotex from importing products from its Indian facilities citing “significant concerns” about how research data was handled. The Federal court subsequently cancelled the ban and allowed Apotex to import from India. However, Health Canada put inspectors in Apotex’s Canadian facilities and retested any product from India before allowing them to be sold in Canada.

Apotex is currently suing the government for $500 million, claiming financial and reputational damage from the ban. Morneau sits on the cabinet committee on litigation management. While the $500-million claim has received most of the attention, Apotex’s suit includes another provision: they want a data-integrity requirement dropped for new drug applications, making it easier to sell drugs in Canada —potentially including those manufactured in India.